SANOFI-AVENTIS (EPA:SAN) Press Release: Completed XTEND-Kids Phase 3 study strengthens potential of ALTUVIIIOTM to redefine expectations for treatment of children <12 years of age with hemophilia A
Directive transparence : information réglementée
02/03/2023 08:00
18/03/2023 15:00
16/03/2023 21:06
14/03/2023 19:27
02/03/2023 08:00
24/02/2023 17:16
23/02/2023 22:00
13/02/2023 08:30
03/02/2023 07:30
17/01/2023 20:44
17/01/2023 20:27